Inactive Instrument

Curis, Inc. Stock price Nasdaq

Equities

US2312691015

Biotechnology & Medical Research

Sales 2024 * 8.35M Sales 2025 * 8.74M Capitalization 64.07M
Net income 2024 * -49M Net income 2025 * -55M EV / Sales 2024 * 7.67 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 7.33 x
P/E ratio 2024 *
-1.79 x
P/E ratio 2025 *
-2 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.75%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 57 16-03-28
Director of Finance/CFO 52 22-07-25
Chief Tech/Sci/R&D Officer - 22-01-02
Members of the board TitleAgeSince
Director/Board Member 71 03-10-31
Chairman 82 00-02-13
Chief Executive Officer 57 16-03-28
More insiders
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
More about the company
  1. Stock
  2. Equities
  3. Stock Curis, Inc.
  4. Stock Curis, Inc. - Nasdaq